The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.
There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (
In summary, challenges like delivery to IP cavity, tumor or organ-specific targeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity, etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinated humans for several decades and are now widely explored in the biomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes, and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy, and gene delivery. Whereas microparticles can be explored for delayed drug delivery to the peritoneal cavity due to relatively slow removal from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance between benefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to get the best out of this route of drug administration.
The present book is a link between pharmaceutical scientists (drug formulators), clinicians, toxicologists, and regulatory experts. This book also provides a new perspective to researchers to divert or guide their research in an optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in the medical devices sector to face up and show potential in delivering drugs. It is a chance for commercial partners like insurance companies and the pharma industry to explore this direction.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. For the last many years, she has been working with various multinational pharmaceutical companies in technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research at numerous national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited several trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received numerous prestigious national and international awards among them include recently received the prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, and the role of excipients in delivery systems (www.ranjitas.com).
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur MQCSC58RMN
Quantité disponible : Plus de 20 disponibles
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783031316937_new
Quantité disponible : Plus de 20 disponibles
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Unique compilation of research-clinical-toxicity-regulatory dataUnique collection of DDS (drug delivery systems) explored till nowServes one stop information source for all stages of drug targeting research to peritoneumRanjita Sheg. N° de réf. du vendeur 842326604
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The Peritoneal cavity (PC) isthekey metastatic site for intra-abdominal malignancies (e.g.,GI tract and rectal cancer). PCsitescan be used to target several other diseases where lymphatic drug delivery is desired without dumping largeamountsofthedrug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC),and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapyforcancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understandingoftherole of drug delivery systems (DDS)intargeting drugsinthe intraperitoneal (IP)cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (In summary, challenges like delivery to IP cavity, tumor ororgan-specifictargeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity,etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinatedhumansforseveral decades and are now widely explored inthebiomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes,and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy,and gene delivery. Whereas microparticles can be explored for delayed drug delivery totheperitoneal cavity due to relativelyslowremoval from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance betweenbenefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to getthebest out of this route of drug administration.The presentbook is a link between pharmaceuticalscientists(drugformulators), clinicians,toxicologists,and regulatory experts. This book also providesanew perspective to researchers to divert or guide their research inanoptimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially inthemedical devices sector to face up and show potential in deliveringdrugs. It is a chance for commercial partners like insurance companies andthepharma industry to explore this direction. 244 pp. Englisch. N° de réf. du vendeur 9783031316937
Quantité disponible : 2 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. 1st ed. 2023 edition NO-PA16APR2015-KAP. N° de réf. du vendeur 26396297670
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -The Peritoneal cavity (PC) is the key metastatic site for intra-abdominal malignancies (e.g., GI tract and rectal cancer). PC sites can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amounts of the drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy for cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding of the role of drug delivery systems (DDS) in targeting drugs in the intraperitoneal (IP) cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 252 pp. Englisch. N° de réf. du vendeur 9783031316937
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - The Peritoneal cavity (PC) isthekey metastatic site for intra-abdominal malignancies (e.g.,GI tract and rectal cancer). PCsitescan be used to target several other diseases where lymphatic drug delivery is desired without dumping largeamountsofthedrug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC),and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapyforcancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understandingoftherole of drug delivery systems (DDS)intargeting drugsinthe intraperitoneal (IP)cavity.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (In summary, challenges like delivery to IP cavity, tumor ororgan-specifictargeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity,etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinatedhumansforseveral decades and are now widely explored inthebiomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes,and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy,and gene delivery. Whereas microparticles can be explored for delayed drug delivery totheperitoneal cavity due to relativelyslowremoval from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance betweenbenefit and risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to getthebest out of this route of drug administration.The presentbook is a link between pharmaceuticalscientists(drugformulators), clinicians,toxicologists,and regulatory experts. This book also providesanew perspective to researchers to divert or guide their research inanoptimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially inthemedical devices sector to face up and show potential in deliveringdrugs. It is a chance for commercial partners like insurance companies andthepharma industry to explore this direction. N° de réf. du vendeur 9783031316937
Quantité disponible : 1 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand. N° de réf. du vendeur 401127961
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND. N° de réf. du vendeur 18396297676
Quantité disponible : 4 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Hardcover. Etat : Brand New. 252 pages. 9.25x6.10x9.21 inches. In Stock. N° de réf. du vendeur x-3031316932
Quantité disponible : 2 disponible(s)